Products and Services

Are you interested in Cell Line Development, the development of a New Biological Drug, Biosimilar or an improved bioprocess?

We will bring your project faster to success! UGA Biopharma has longstanding expertise and know-how in cell line development, bioprocess optimization, downstream development and analytics as well as media and feed development. This makes us to an ideal partner for your development projects.

UGA Biopharma - The start has to be right!

 

Ready To Use Biosimilar Cell Lines read more

Adalimumab (Humira®)           
Full package ready for sales now: 
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein
 

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com 

Aflibercept (Zaltrap®)           
Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Anakinra (Kineret®)           
If you have any further question about the licensing conditions, please do not hesitate to contact us via: info@ugabiopharma.com
Bevacizumab (Avastin®)           
Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Certolizumab (Cimzia®)           
If you have any further question about the licensing conditions, please do not hesitate to contact us via: info@ugabiopharma.com
Darbepoetin alfa (Aranesp®)           
Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the Aranesp® originator.
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Dupilumab (Dupixent®)           

A outstanding product concentration higher than 7 g/L could be reached during the Dupilumab development project! The first CHOice® Medium works very well for Dupilumab clones.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Eculizumab (Soliris®)           
Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody). 

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Etanercept (Enbrel®)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Ipilimumab (Yervoy®)           
Typical charge profil of Yervoy®.
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Laronidase (Aldurazyme®)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Natalizumab (Tysabri®)           
The primary structure of a biosimilar has to be identical to the originator molecule. The result of the peptide mapping of the Natalizumab biosimilar is depicted here.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Nivolumab (Opdivo®)           
A product concentration over 3 g/L has been obtained during a Nivolumab consistency run in stirred bioreactors.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Omalizumab (Xolair®)           
A product concentration of 3 g/L has been obtained during the Omalizumab biosimilar development project.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Pembrolizumab (Keytruda®)           
Pembrolizumab (IgG4) biosimilar development project has been finalized in a very short time line – according to the High Speed Workflow of UGA Biopharma!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Pertuzumab (Perjeta®)           
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Vedolizumab Pools (Entyvio®)           
Pool stage finalized. On request, stable Vedolizumab clones can be developed within weeks!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Under Development

Alirocumab (Praluent®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Imiglucerase (Cerezyme®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Mepolizumab (Nucala®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Dulaglutide (Trulicity®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Elosulfase (Vimzim®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Emicizumab (Hemlibra®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Erenumab (Aimovig®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Galsulfase (Naglazyme®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Idursulfase (Elaprase®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Panitumumab (Vectibix®)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com




Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900